ES
Therapeutic Areas
Gallop Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LYT-200 | Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) | Phase 1/2 |
| Drug | Indication | Phase |
|---|---|---|
| LYT-200 | Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) | Phase 1/2 |